French COhoRte Extra-Vascular Implantable CardiovErter DefibrillatoR
Implantable cardioverter-defibrillators (ICDs) are widely recognized for their efficacy in reducing the risk of sudden cardiac death in high-risk patients. Nonetheless, there remains significant scope for improving outcomes through advancements in device technology and design. The extravascular cardioverter-defibrillat
| Condition(s) | Defibrillators, Implantable, Sudden Cardiac Death Due to Cardiac Arrhythmia |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Implantable cardioverter-defibrillators (ICDs) are widely recognized for their efficacy in reducing the risk of sudden cardiac death in high-risk patients. Nonetheless, there remains significant scope for improving outcomes through advancements in device technology and design. The extravascular cardioverter-defibrillator (EV-ICD) represents such an innovation, offering key advantages over other ICD systems. It incorporates a lead positioned in the substernal space, enabling the delivery of pause-prevention security pacing, antitachycardia pacing, and defibrillation energy similar to that provided by conventional transvenous ICDs. Previous studies have demonstrated that EV-ICDs can be implanted safely and are capable of terminating majority of induced ventricular arrhythmias during implanta |
| Who can participate | Inclusion Criteria: * All patients undergoing EV-ICD implantation Exclusion Criteria: * Refusal of consent |
| Sex | All |
| Lead sponsor | Paris Sudden Death Expertise Center |
| Locations | Paris, France |
| Start date | 2024-02-01 |
| NCT ID | NCT06739239 |
| Official listing | https://clinicaltrials.gov/study/NCT06739239 |